ivabradine has been researched along with Chagas Cardiomyopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demacq, C; Gimpelewicz, CR; Gómez, EA; Martinez, F; McMurray, JJV; Packer, M; Ramires, FJA; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Bocchi, EA; Rassi, S; Veiga Guimarães, G | 1 |
2 other study(ies) available for ivabradine and Chagas Cardiomyopathy
| Article | Year |
|---|---|
Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et
Topics: Chagas Cardiomyopathy; Chagas Disease; Heart; Heart Failure; Humans; Ivabradine | 2018 |
Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
Topics: Aminobutyrates; Biphenyl Compounds; Chagas Cardiomyopathy; Drug Combinations; Heart Failure; Humans; Ivabradine; Tetrazoles; Valsartan | 2018 |